Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts
2005

Effects of rapamycin and cotylenin A on breast cancer cells

Sample size: 20 publication 10 minutes Evidence: high

Author Information

Author(s): Kasukabe Takashi, Okabe-Kado Junko, Kato Nobuo, Sassa Takeshi, Honma Yoshio

Primary Institution: Saitama Cancer Center

Hypothesis

Can the combination of rapamycin and cotylenin A enhance the growth-inhibitory effects on MCF-7 breast cancer cells?

Conclusion

The combination of rapamycin and cotylenin A significantly inhibits the growth of MCF-7 breast cancer cells both in vitro and in vivo.

Supporting Evidence

  • The combination treatment induced growth arrest at the G1 phase rather than apoptosis.
  • Gene expression analysis showed significant modulation of several genes in treated MCF-7 cells.
  • Combined treatment significantly inhibited tumor growth in xenograft models.

Takeaway

Using two medicines together can help stop breast cancer cells from growing better than using just one medicine alone.

Methodology

The study used MTT assays, trypan blue dye exclusion tests, and cDNA microarray analysis to evaluate the effects of treatments on MCF-7 cells and xenografts.

Limitations

The study primarily focused on one breast cancer cell line and may not generalize to all breast cancer types.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/bcr1344

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication